Brussels, Belgium, 16 March 2022 - Precirix NV , a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital , Jeito Capital and Forbion as co-leads.
"We are delighted to announce this major milestone and are grateful for the strong investor support. ...
Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
Advert